CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The goal of this clinical research study is to learn if the combination of lenalidomide and rituximab can help to control CLL. The safety of this dru...
Phase 2
Houston, Texas, United States
monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also all...
Phase 1
Houston, Texas, United States and 20 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Houston, Texas, United States and 70 other locations
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...
Phase 3
Houston, Texas, United States and 83 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Houston, Texas, United States and 130 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Kingwood, Texas, United States and 230 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Houston, Texas, United States and 179 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Houston, Texas, United States and 79 other locations
) and prednisone).The study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic...
Phase 1, Phase 2
Houston, Texas, United States and 76 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Houston, Texas, United States and 216 other locations
Clinical trials
Research sites
Resources
Legal